Yifeng Pharmacy - Asset Resilience Ratio
Yifeng Pharmacy (603939) has an Asset Resilience Ratio of 19.16% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2015–2024)
This chart shows how Yifeng Pharmacy's Asset Resilience Ratio has changed over time. Check Yifeng Pharmacy (603939) strategic asset index to assess the company's strategic physical and investment asset allocation.
Liquid Assets Composition Over Time
This chart breaks down Yifeng Pharmacy's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see market cap of Yifeng Pharmacy.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥4.99 Billion | 19.16% |
| Total Liquid Assets | CN¥4.99 Billion | 19.16% |
Asset Resilience Insights
- Good Liquidity Position: Yifeng Pharmacy maintains a healthy 19.16% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company has significant short-term investments, indicating active treasury management.
Yifeng Pharmacy Industry Peers by Asset Resilience Ratio
Compare Yifeng Pharmacy's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Raia Drogasil S.A
SA:RADL3 |
Pharmaceutical Retailers | 0.38% |
|
Dashenlin Pharm Grp Co Ltd
SHG:603233 |
Pharmaceutical Retailers | 0.80% |
|
Sastasundar Ventures Limited
NSE:SASTASUNDR |
Pharmaceutical Retailers | 2.38% |
|
Empreendimentos Pague Menos S.A
SA:PGMN3 |
Pharmaceutical Retailers | 0.00% |
|
d1000 Varejo Farma Participações S.A
SA:DMVF3 |
Pharmaceutical Retailers | 2.05% |
|
High Tide Inc
V:HITI |
Pharmaceutical Retailers | 0.03% |
|
Medplus Health Services Limited
NSE:MEDPLUS |
Pharmaceutical Retailers | 10.54% |
|
Laobaixing Pharmacy
SHG:603883 |
Pharmaceutical Retailers | 0.01% |
Annual Asset Resilience Ratio for Yifeng Pharmacy (2015–2024)
The table below shows the annual Asset Resilience Ratio data for Yifeng Pharmacy.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 15.75% | CN¥4.41 Billion ≈ $644.85 Million |
CN¥27.97 Billion ≈ $4.09 Billion |
+9.00pp |
| 2023-12-31 | 6.76% | CN¥1.63 Billion ≈ $238.63 Million |
CN¥24.14 Billion ≈ $3.53 Billion |
+6.52pp |
| 2022-12-31 | 0.24% | CN¥50.05 Million ≈ $7.32 Million |
CN¥21.04 Billion ≈ $3.08 Billion |
-0.65pp |
| 2021-12-31 | 0.89% | CN¥152.19 Million ≈ $22.27 Million |
CN¥17.05 Billion ≈ $2.50 Billion |
-4.86pp |
| 2020-12-31 | 5.75% | CN¥744.84 Million ≈ $108.99 Million |
CN¥12.95 Billion ≈ $1.89 Billion |
+3.65pp |
| 2019-12-31 | 2.11% | CN¥193.23 Million ≈ $28.28 Million |
CN¥9.18 Billion ≈ $1.34 Billion |
-1.61pp |
| 2018-12-31 | 3.72% | CN¥292.76 Million ≈ $42.84 Million |
CN¥7.87 Billion ≈ $1.15 Billion |
-15.89pp |
| 2017-12-31 | 19.61% | CN¥937.87 Million ≈ $137.24 Million |
CN¥4.78 Billion ≈ $699.84 Million |
-15.49pp |
| 2016-12-31 | 35.10% | CN¥1.48 Billion ≈ $216.80 Million |
CN¥4.22 Billion ≈ $617.70 Million |
+24.55pp |
| 2015-12-31 | 10.55% | CN¥257.00 Million ≈ $37.61 Million |
CN¥2.44 Billion ≈ $356.56 Million |
-- |
About Yifeng Pharmacy
Yifeng Pharmacy Chain Co., Ltd. engages in the retail business of pharmaceutical products in China. The company operates through Retail business and Wholesale business segments. It offers Western and Chinese patent medicine, traditional Chinese medicine herbal pieces, medical devices and equipment, health supplements and products, personal care products, drugs, and convenience products related to… Read more